Clinical trials: Healty Volunteers
Healty Male Volunteers
CKD-397 Drug-drug Interaction Study (B)
The purpose of this study is to investigate to effect of tadalafil on the pharmacokinetic properies of tamsulosin
- Trial name
- CKD-397DDI(B) (NCT02247505)
- Testing
- Harnal-D Cap. 0.2mg, Cialis Tab. 5mg
- Where
- South Korea
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Volunteers
A Study of the Safety,Tolerability,and Pharmacokinetics of Multiple-Ascending Dose JS1-1-01 in Healty Subjects.
The purpose of this study is to evaluate the safety，tolerability，and pharmacokinetics of multiple-accending dose of JS1-1-01。
- Trial name
- NCT05656274
- Testing
- JS1-1-01
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Healthy
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2201 and Co-administration of Each Component in Healty Male Volunteers
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2201 and co-administration of each component in fasting condition in healthy male volunteers.
- Trial name
- NCT05737082
- Testing
- HCP2201, RLD2205, RLD2206
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy Volunteers - Male and Female
A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults
This is a Phase 1, single-center, randomized, single-blind (participants are blinded), placebo controlled, four-way cross over TQT study (4×4 Williams square design) to investigate the effect of KP-001 on the QTc interval using…
- Trial name
- NCT06649942
- Testing
- KP-001, Moxifloxacin 400 mg
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kaken Pharmaceutical
Healty Volunteers
To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers
Part 1 will evaluate the effects of KP-001 as an inhibitor of BCRP on the PK of rosuvastatin. In the Treatment Period 1, a single dose of rosuvastatin will be administered.
- Trial name
- NCT06821698
- Testing
- KP-001, Rosuvastatin calcium10mg, Caffeine citrate
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Kaken Pharmaceutical
Health
Bioequivalence Study Between UI009 and UIC202005 in Healthy Subjects
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Evaluate Bioequivalence After Dry-powder Inhalation of UIC202005 or UI009 in Healty Volunteers
- Trial name
- NCT07110740
- Testing
- UI009, UIC202005
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
Influenza
Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers
This study assesses safety, tolerability and immunogenicity of NBP607QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease.
- Trial name
- NCT03826719
- Testing
- NBP607QIV, Agrippal
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Healty Volunteers, Preventable Disease, Vaccine
A Phase 2 Bridging Study to Assess the New Formulation of ETVAX
This is a phase 2,prospective double-blind, randomized, parallel-group study with the aim to demonstrate non-inferiority, in terms of immunogenicity, between the wet formulation and a newly developed partially dried formulation…
- Trial name
- NCT05178134
- Testing
- Etvax
- Where
- Sweden
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Scandinavian Biopharma AB
Schizophrenia
First Time in Human Study With GSK1018921
GSK1018921 is a new drug under development for the treatment of schizophrenia. GSK1018921 differs from other available drugs in its mode of action and it is assumed that it may have an effect in the treatment of so-called…
- Trial name
- NCT00527020
- Testing
- GSK1018921, Nicotine Lozenges
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hyperlipidemias
A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-221 in healthy male subjects.
- Trial name
- NCT05202405
- Testing
- AD-221, AD-221A and AD-221B
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.